Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + olmesartan
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atorvastatin + olmesartan is a combination of two pharmaceutical agents used primarily for the management of cardiovascular risk factors. Atorvastatin is a statin (HMG-CoA reductase inhibitor) that lowers cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver, thereby reducing low-density lipoprotein (LDL) cholesterol and overall cardiovascular risk. Olmesartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, resulting in vasodilation and reduced blood pressure. The combination may be considered in patients who require both lipid-lowering therapy and antihypertensive treatment.
- Other names
- atorvastatin and olmesartanatorvastatin plus olmesartan
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on atorvastatin + olmesartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + olmesartan.